Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes

ClinicalTrials.gov processed this data on June 27, 2024. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified June 2024 by Medical University of South Carolina, American Hearing Research Foundation, Cures Within Reach

Sponsor

Medical University of South Carolina

Information Provided by (Responsible Party)

Habib Rizk,MD

Clinicaltrials.gov Identifier

NCT04218123
Other Study ID Numbers: 00091200
First Submitted: December 30, 2019
First Posted: January 6, 2020
Results First Posted: June 24, 2024
Last Update Posted: July 23, 2024
Last Verified: June 2024
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Meniere Disease
  • Drug: Venlafaxine
  • Drug: Placebo oral tablet

Study Design

Study TypeInterventional
Actual Enrollment40 participants
Design AllocationRandomized
Interventional ModelCrossover Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleAssessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Study Start DateFebruary 5, 2020
Actual Primary Completion DateSeptember 13, 2023
Actual Study Completion DateSeptember 14, 2023

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Venlafaxine Arm
  • Drug: Venlafaxine
    • Daily oral intake 37.5 mg
  • Placebo
  • Drug: Placebo oral tablet

    Outcome Measures

    Primary Outcome Measures

    1. Number of Vertigo Episodes [6 months]
      Patients will be keeping a diary throughout the study period and beyond.
    2. Severity of Vertigo [6 months]
      The study team will use a modified version of vertigo control classification because the treatment phases are 2 months long and the study team will not be able to wait 18-24 months after treatment to assess efficacy per academy guidelines. Previous studies have defined four categories of response to treatment: 1) very good response if more than 75% reduction in vertigo spells frequency and/or intensity, 2) good response if 50-75% reduction, 3) fair response if 25-50% reduction, and 4) poor response if less than 25% reduction.

      The vertigo classes will be defined as follows; Class A: 0 (complete control of vertigo) Class B: 0-40 or >60% reduction in mean vertigo episode severity (good control of vertigo) Class C: 41-80 or 20-60% reduction in severity (fair control of vertigo) Class D: 81-120 or -20-20% reduction in severity (no change in vertigo) Class E: >120 or >20% worsening in severity (worse vertigo)

    Secondary Outcome Measures

    1. Change in Score on The Medical Outcomes Study 20-item Short Form Health Survey [Baseline to end of treatment (6 months)]
      The Medical Outcomes Study 20-item Short Form Health Survey is a 20-item general health questionnaire to assess quality of life in chronic diseases. It assesses 6 areas of health: physical functioning, role functioning, social functioning, mental health, health perceptions, and pain. Each score ranges between 0 and 100, with 100 indicating best possible function and 0 the worst possible function.
    2. Change in Score on The Meniere's Disease Patient-Oriented Symptom Index (MDPOSI) [Baseline to end of treatment (6 months)]
      The Meniere's Disease Patient-Oriented Symptom Index is a 23-item survey developed as a MD-specific tool to assess the impact of MD symptoms on patients' lives. The score ranges from 0 to 100 with the higher score indicating an active disease with significant impact on function and quality of life.
    3. Change in Score on Penn State Worry Questionnaire (PSWQ) [Baseline to end of treatment (6 months)]
      The PSWQ is a 16-item survey for assessment of anxiety which has been used to identify generalized anxiety disorder. Scores range from 16 (Low worry) to 80 (high worry). A score higher than 60 is indicative of significant anxiety and risk for an anxiety disorder
    4. Change in Score on Patient Health Questionnaire (PHQ9) [Baseline to end of treatment (6 months)]
      The Patient Health Questionnaire is a 9-item survey which assesses the severity of depression. A low score is indicative of little to no depressive symptoms, and a high score is indicative of Moderately severe to severe depressive symptoms. Scores range from 0 to 27 with scores higher than 20 indicative of significant risk for depression and scores below 10 indicative at most of a mild depression.
    5. Change in Score on Cognitive Failure Questionnaire (CFQ) [Baseline to end of treatment (6 months)]
      The Cognitive Failure Questionnaire is a 25-item survey which assesses cognitive and executive function not tied to any specific disease state. It aims to assess perception, memory, and motor function in everyday tasks.The score ranges from 0 to 100 The higher score on the CFQ, the more frequent the cognitive failures experienced by the subject
    6. Change in Score on Neuropsychological Vertigo Inventory (NVI) [Baseline to end of treatment (6 months)]
      The English version of the Neuropsychological Vertigo Inventory consists of 28-items with a 5-point Likert scale for each question. It is a cognitive assessment specific to patients with dizziness. The NVI assesses 7 domains of cognition: space perception, attention, time perception, memory, emotional, visual/ocular and motor. The score ranges from 0 to 140. The higher the score on the NVI the worse the cognitive function of the subject.
    7. Change in Score on Dizziness Handicap Inventory (DHI) [Baseline to end of treatment (6 months)]
      The Dizziness Handicap Inventory is a 25-item questionnaire of self-perceived handicap from dizziness.There are 7 questions in the physical domain, 9 in the emotional domain, and 8 in the functional domain. It is scored from 0 (no perceived disability) to 100 (maximum perceived disability).

    Eligibility Criteria

    Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • e prospectively recruited from the population of patients presenting with dizziness to our tertiary, multidisciplinary, vestibular-focused, neurotology clinic. Subjects must meet the following inclusion criteria:
    • be 18 years of age or older;
    • have definite MD as defined by the Barany Society 2015 international consensus statement;
    • have active MD with at least 2 vertigo episodes in the month prior to enrollment; and score at least 36 on the Dizziness Handicap Inventory (DHI), representing at least moderate handicap.
    • Patients with the following will be excluded:
    • other concurrent vestibular or balance disorder (especially those with vestibular migraine-related vertigo episodes despite not meeting diagnostic criteria for vestibular migraine);
    • currently taking venlafaxine, SSRIs, or SNRIs;
    • history of medical (e.g. gentamicin) or surgical (e.g. labyrinthectomy) vestibular ablative treatment;
    • history of otologic, lateral skull base, or brain surgery;
    • history of radiation to the head or neck;
    • known neurologic disorder affecting cognition;
    • currently taking another serotonin modulating medication;
    • seizures;
    • stroke;
    • myocardial infarction;
    • hepatic or renal impairment;
    • hyperlipidemia;
    • coagulopathy;
    • psychiatric disorder other than anxiety or depression;
    • glaucoma;
    • uncontrolled hypertension;
    • pregnancy or in
    Exclusion Criteria
    • e prospectively recruited from the population of patients presenting with dizziness to our tertiary, multidisciplinary, vestibular-focused, neurotology clinic. Subjects must meet the following inclusion criteria:
    • be 18 years of age or older;
    • have definite MD as defined by the Barany Society 2015 international consensus statement;
    • have active MD with at least 2 vertigo episodes in the month prior to enrollment; and score at least 36 on the Dizziness Handicap Inventory (DHI), representing at least moderate handicap.
    • Patients with the following will be excluded:
    • other concurrent vestibular or balance disorder (especially those with vestibular migraine-related vertigo episodes despite not meeting diagnostic criteria for vestibular migraine);
    • currently taking venlafaxine, SSRIs, or SNRIs;
    • history of medical (e.g. gentamicin) or surgical (e.g. labyrinthectomy) vestibular ablative treatment;
    • history of otologic, lateral skull base, or brain surgery;
    • history of radiation to the head or neck;
    • known neurologic disorder affecting cognition;
    • currently taking another serotonin modulating medication;
    • seizures;
    • stroke;
    • myocardial infarction;
    • hepatic or renal impairment;
    • hyperlipidemia;
    • coagulopathy;
    • psychiatric disorder other than anxiety or depression;
    • glaucoma;
    • uncontrolled hypertension;
    • pregnancy or intention of pregnancy.

    Contacts and Locations

    Sponsors and Collaborators Medical University of South Carolina, American Hearing Research Foundation, Cures Within Reach
    American Hearing Research Foundation, Cures Within Reach
    Locations
    • Medical Univeristy of South Carolina | Charleston, South Carolina, United States, 29425
    Investigators
    • Principal Investigator: Habib Rizk, MD, Medical University of South Carolina

    Study Documents (Full Text)

    More Information

    Additional Relevant MeSH Terms

    • Meniere Disease
    • Endolymphatic Hydrops
    • Labyrinth Diseases
    • Ear Diseases
    • Otorhinolaryngologic Diseases